MX2022014858A - Formas solidas de pralsetinib. - Google Patents

Formas solidas de pralsetinib.

Info

Publication number
MX2022014858A
MX2022014858A MX2022014858A MX2022014858A MX2022014858A MX 2022014858 A MX2022014858 A MX 2022014858A MX 2022014858 A MX2022014858 A MX 2022014858A MX 2022014858 A MX2022014858 A MX 2022014858A MX 2022014858 A MX2022014858 A MX 2022014858A
Authority
MX
Mexico
Prior art keywords
solid forms
pralsetinib
pyrazol
methyl
forms
Prior art date
Application number
MX2022014858A
Other languages
English (en)
Inventor
Lauren Maceachern
Joshua Waetzig
Gordon D Wilkie
Kimberly Jean Miller
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2022014858A publication Critical patent/MX2022014858A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

El compuesto cis)-N-((S)-1-(6-(4-fluoro-1H-pirazol-1-il)piridin-3- il)etil)-1-metoxi-4-(4 metil-6-(5-metil-1H-pirazol-3-ilamino)pirim idin-2-il)ciclohexancarboxamida se puede preparar como una base libre en diversas formas sólidas cristalinas y en diversas formas de sal, cada una teniendo una o más formas sólidas.
MX2022014858A 2020-05-29 2021-05-28 Formas solidas de pralsetinib. MX2022014858A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032121P 2020-05-29 2020-05-29
US202063047353P 2020-07-02 2020-07-02
PCT/US2021/034823 WO2021243192A1 (en) 2020-05-29 2021-05-28 Solid forms of pralsetinib

Publications (1)

Publication Number Publication Date
MX2022014858A true MX2022014858A (es) 2023-02-23

Family

ID=76601779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014858A MX2022014858A (es) 2020-05-29 2021-05-28 Formas solidas de pralsetinib.

Country Status (12)

Country Link
US (1) US20230295121A1 (es)
EP (1) EP4157829A1 (es)
JP (1) JP2023527412A (es)
KR (1) KR20230017234A (es)
CN (1) CN116075503A (es)
AU (1) AU2021281365A1 (es)
BR (1) BR112022024382A2 (es)
CA (1) CA3183728A1 (es)
IL (1) IL298523A (es)
MX (1) MX2022014858A (es)
TW (1) TW202210468A (es)
WO (1) WO2021243192A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
WO2022086899A1 (en) * 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of pralsetinib and process for preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3371171T3 (fi) 2015-11-02 2024-01-10 Blueprint Medicines Corp Ret:n estäjiä

Also Published As

Publication number Publication date
EP4157829A1 (en) 2023-04-05
TW202210468A (zh) 2022-03-16
IL298523A (en) 2023-01-01
US20230295121A1 (en) 2023-09-21
KR20230017234A (ko) 2023-02-03
BR112022024382A2 (pt) 2023-05-02
CN116075503A (zh) 2023-05-05
JP2023527412A (ja) 2023-06-28
AU2021281365A1 (en) 2022-12-15
WO2021243192A1 (en) 2021-12-02
CA3183728A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2022014858A (es) Formas solidas de pralsetinib.
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
MY145281A (en) Novel compounds
WO2007027238A3 (en) Jak kinase inhibitors and their uses
MXPA05012762A (es) Derivados de la quinazolina macrociclica como agentes antiproliferativos.
MX346822B (es) Pro-drogas de compuestos de 2,4-pirimidindiamina y sus usos.
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
MY145447A (en) Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
UY27567A1 (es) Compuestos cristalinos novedosos
TNSN08029A1 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
SE0202463D0 (sv) Novel compounds
HK1079519A1 (en) Furyl compounds
MX2010004576A (es) Derivados de pirimidina novedosos.
SG196855A1 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
UA95230C2 (ru) ЗАМЕЩЕННЫЕ ТЕТРАГИДРОПИРИМИДО[4,5-d]ПИРИМИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
HK1088890A1 (en) Biguanide and dihydrotriazine derivatives
IL180551A0 (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
IL164606A0 (en) Novel compounds
PL1807431T3 (pl) Pirolo[1,2-d][1,2-4]triazyny jako inhibitory C-Jun N-końcowych kinaz (JNK) i kinaz P-38
TW200738723A (en) 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof
MXPA04012217A (es) Amidas insecticidas con sistemas de anillos biciclicos benzo-fusionados que contienen nitrogeno.
SG151288A1 (en) 3-cyano-quinoline derivatives with antiproliferative activity